Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
|
|
- Diana Allison
- 5 years ago
- Views:
Transcription
1 Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
2 The fascinating history of Herceptin Murine HER2 / neu gene cloned Human HER2 gene cloned mumab 4D5 Phase I IND for rhumab HER2 Paclitaxel + H and H mono US approval Paclitaxel + H and H mono EU approval Adjuvant H approval 1st IA of HERA HERA 2-year follow-up HERA 4-year follow-up and 1-year H vs 2-year H IA Association of HER2 with poor clinical outcome HERA recruitment opens HERA final analysis 1-year H vs 2-year H HER2, human epidermal growth factor receptor 2; H, Herceptin; IA, interim analysis
3 HERA study design HER2-positive early breast cancer (IHC 3+ and / or FISH+) n=5102 Surgery + (neo)adjuvant chemotherapy + radiotherapy Observation Herceptin q3w x 1 year Herceptin q3w x 2 years Option to cross over to Herceptin (after IA 2005) IHC, immunohistochemistry; FISH, fluorescence in situ hybridisation
4 End points of the HERA trial Primary end point DFS 1-year Herceptin vs observation 2-year Herceptin vs observation Secondary end points OS, RFS, distant DFS, safety 1-year Herceptin vs observation 2-year Herceptin vs observation compare DFS, OS, RFS, distant DFS and safety 1-year Herceptin vs 2-year Herceptin DFS, disease-free survival; OS, overall survival; RFS, relapse-free survival
5 HERA 2008 interim analysis: 2-year vs 1-year Herceptin Statistical assumptions HR <0.80 DFS absolute reduction 4.9% 5-year DFS 1-year arm: 70% 5-year DFS 2-year arm: 74.9% p value <0.014 for early release of results 2008 interim analysis 500 events reached June 2008 October 2008 IDMC advises Executive Committee Interim analysis positive Data release at SABCS HR, hazard ratio; IDMC, Independent Data Monitoring Committee Database cleaning Trial continues as planned No data release Final analysis triggered by 725 events (~2011)
6 HERA: IDMC recommendations October 2008 Do not release information on the 2-year Herceptin arm Continue the 1-year Herceptin vs 2-year Herceptin comparison Release updated information on 1-year Herceptin vs observation No conclusions can be drawn regarding the efficacy of Herceptin therapy for 2 years vs 1 year
7 HERA study design HER2-positive early breast cancer (IHC 3+ and / or FISH+) n=5102 Surgery + (neo)adjuvant chemotherapy + radiotherapy Observation Herceptin q3w x 1 year Herceptin q3w x 2 years Option to cross over to Herceptin (after IA 2005)
8 HERA: DFS and OS over time 1 and 2 years follow-up Median follow-up (% follow-up time after selective crossover) DFS benefit No. of DFS events H 1 year vs observation Median follow-up (% follow-up time after selective crossover) OS benefit No. of deaths H 1 year vs observation year (0%) 127 vs 220 p< year (0%) 29 vs 37 p= years (4.3%) 218 vs 321 p< years (4.1%) 59 vs 90 p= Favours 1 Favours no 2 Herceptin HR Herceptin 0 Favours 1 Favours no 2 Herceptin HR Herceptin 1 Piccart-Gebhart et al 2005; 2 Smith et al 2007
9 DFS (ITT): 4-year median follow-up Patients (%) year Herceptin Observation 6.4% Events year DFS HR % CI 0.66, Months from randomisation p value < No. at risk
10 OS (ITT): 4-year median follow-up Patients (%) Observation 1-year Herceptin 1.6% Events year DFS HR % CI 0.70, Months from randomisation p value No. at risk
11 HERA: DFS and OS over time Median follow-up (% follow-up time after selective crossover) DFS benefit No. of DFS events H 1 year vs observation Median follow-up (% follow-up time after selective crossover) OS benefit No. of deaths H 1 year vs observation year (0%) 127 vs 220 p< year (0%) 29 vs 37 p= years (4.3%) 218 vs 321 p< years (4.1%) 59 vs 90 p= years (33.8%) 369 vs 458 p< years (30.9%) 182 vs 213 p= Favours 1 Favours no 2 Herceptin HR Herceptin 0 Favours 1 Favours no 2 Herceptin HR Herceptin 1 Piccart-Gebhart et al 2005; 2 Smith et al 2007
12 Specific question 1 Crossover to Herceptin of 52% of the patients originally allocated to observation disrupted the randomised comparison between 1-year Herceptin and observation Question: To what extent might crossover have biased the ITT analysis?
13 Flow chart of observation patients: by status on 16 May patients originally randomised to observation 344 patients 1354 patients 16 May DFS event or lost to follow-up 2005 alive and disease-free 198 alive post DFS event 469 patients remained on observation 344 patients ineligible for crossover
14 Time to selective crossover by calendar date (n=885) Proportion 0.6 Switched to Herceptin No. at risk Observation May Aug Nov Mar Jun Sep Dec Randomisation to 1st dose Diagnosis to 1st dose Follow-up from 1st dose Median time (range), months 22.8 (<1-52.7) 30.9 ( ) 29.1 ( )
15 Baseline characteristics of observation patients alive and disease free on 16 May 2005 Compared to patients who did not selectively cross over to Herceptin, those who did were more likely to: be younger have received anthracyclines and anthracyclines plus taxanes be diagnosed with node-positive disease have hormone receptor-positive tumours
16 Specific question of 1354 patients (65%) in the observation group who were alive and disease free on May crossed over and received Herceptin Questions: What was the course of disease in the subgroups of observation patients who did or did not cross over to active therapy? Is there any effect of the late introduction of Herceptin?
17 Landmark of 16 May 2005 The landmark analysis considers only patients who were alive and disease free on 16 May 2005
18 DFS (landmark analysis): Herceptin vs observation Patients alive and disease free (%) Observation: Alive and disease free on 16 May 2005 Herceptin: Alive and disease free on 16 May 2005 No. at risk Months from randomisation
19 DFS (landmark analysis): observation (alive, no DFS event), selective crossover and no crossover Patients alive and disease free (%) No. at risk 20 Observation: Alive and disease free on 16 May 2005 Selective crossover 0 No crossover Months from randomisation
20 OS (landmark analysis): Herceptin vs observation Patients alive and disease free (%) No. at risk Observation: Alive and disease free on 16 May 2005 Herceptin: Alive and disease free on 16 May Months from randomisation
21 OS (landmark analysis): crossover vs no-crossover Patients alive (%) No. at risk Observation: Alive and disease free on 16 May 2005 Selective crossover No crossover Months from randomisation
22 Cardiac safety: safety analysis population a No. patients (%) Cardiac death Severe CHF (NYHA III and IV) Symptomatic CHF (II, III and IV) Confirmed significant LVEF drop Herceptin discontinued due to cardiac problems Observation a n= (0.1) 0 (0.0) 3 (0.2) 13 (0.8) 1-year Herceptin n= (0.0) 13 (0.8) 33 (2.0) 62 (3.7) 87 (5.2) a Patients who crossed over are censored from the date of starting Herceptin treatment CHF, congestive heart failure; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction
23 Cardiac safety: observation group Cardiac death Severe CHF (NYHA III and IV) Symptomatic CHF (II, III and IV) Confirmed significant LVEF drop Herceptin discontinued due to cardiac problems No crossover after 16 May 05 n=469 0 (0.0) 0 (0.0) 1 (0.2) 5 a (1.1) Crossover n=885 0 (0.0) 0 (0.0) 9 (1.0) 26 (2.9) 43 (4.9) a For 3 of the patients, the LVEF drop occurred between 16 May 05 and the date of the patient decision and may have influenced the patient decision
24 HERA 4-year follow-up data: summary (1) The updated analysis at 4 years was limited to 1-year Herceptin vs observation as recommended by IDMC Extensive selective crossover of observation patients to active therapy biased the ITT comparison Landmark analysis of observation patients who were disease free on 16 May 2005 explored the effects of later introduction of Herceptin Lack of randomisation limits the interpretation of the landmark analysis different outcome due to drug effect or patient characteristics?
25 HERA 4-year follow-up data: summary (2) In HERA, the DFS benefit associated with Herceptin is maintained at 4-year median follow-up 50% of patients in the observation arm crossed over to Herceptin treatment, therefore the OS benefit is no longer statistically significant Patients crossing over at a later date appear to benefit from 1 year of Herceptin
26 HERA: conclusions and next steps 4-year follow-up data support the hypothesis that the risk of relapse in HER2-positive early breast cancer persists over time Prolonged exposure to the Herceptin antibody may improve efficacy This is being tested in the comparison of the 1-year and 2-year groups in the HERA study
27 Additional studies demonstrate consistent DFS benefit for Herceptin HERA CTx H 1 year B-31 / N9831 AC PH BCIRG 006 AC TH TCarboH DFS benefit Median follow-up, years NOAH CTx / H H 1 year 3 FinHer a VH / TH CEF b PACS-04 a CTx H 1 year n=231 n= Favours 1 Favours no 2 Herceptin HR Herceptin a Based on small subgroups of patients with HER2-positive breast cancer; Gianni et al 2008; b DDFS; CTx, chemotherapy; AC, doxorubicin, cyclophosphamide; Gianni et al 2009; Joensuu et al 2009; P, paclitaxel; T, docetaxel; Carbo, carboplatin; V, vinorelbine; Slamon et al 2006; Perez et al 2007; CEF, cyclophosphamide, epirubicin, 5-fluorouracil Smith et al 2007; Spielmann et al 2007
28 1-year Herceptin treatment consistently reduces the risk of death by one-third OS benefit Median follow-up, years HERA CTx H 1 year 4 B-31 / N9831 AC PH 3 BCIRG 006 AC TH 3 TCarboH 3 FinHer VH / TH CEF n= Favours 1 Favours no 2 Herceptin HR Herceptin Gianni et al 2009; Joensuu et al 2009; Slamon et al 2006; Perez et al 2007; Smith et al 2007
29 HER2-positive breast cancer: outstanding questions Concurrent or sequential Herceptin therapy? Herceptin efficacy in lower-risk patients? Optimal treatment duration? Translational research? New combinations? ALTTO (Herceptin + lapatinib) BETH (Herceptin + Avastin)
30 ALTTO: Phase III randomised open-label trial comparing adjuvant lapatinib +/ Herceptin HER2-positive early breast cancer (n=8000) Surgery and completion of (neo)adjuvant anthracycline-based chemotherapy No taxane Concurrent taxanes e for 12 weeks H a q3w for 52 weeks L b qd for 52 weeks H c qw for 12 weeks L d qd + H c q3w for 52 weeks H a q3w for 52 weeks L b qd for 52 weeks H c qw for 12 weeks L d qd + H c q3w for 52 weeks 6-week washout 6-week washout L b qd for 34 weeks L b qd for 34 weeks a Herceptin 8 mg/kg iv loading dose followed by 6 mg/kg q3w; b Lapatinib 1500 mg; c Herceptin 4 mg/kg iv loading dose followed by 2 mg/kg qw; d Lapatinib 1000 mg; e Paclitaxel 80 mg/m 2 qw or docetaxel q3w
31 BETH: Phase III randomised trial comparing Herceptin-containing adjuvant regimens +/ Avastin Resected node-positive or high-risk node-negative HER2-positive early breast cancer n~3600 (maximum) a CTx b + Herceptin CTx b + Herceptin + Avastin Herceptin continued q3w until 1 year total Herceptin + Avastin continued q3w until 1 year total Primary endpoint: DFS Secondary endpoints: OS; RFS; distant recurrence-free interval; safety; biomarker analysis a Actual recruitment to date ~300; b Docetaxel 75 mg/m 2 q3w + carboplatin AUC 6 q3w or docetaxel 100 mg/m 2 FEC; CTx, chemotherapy; q3w, three weekly
32 Conclusions 1 year of Herceptin remains the most appropriate and evidence-based approach for patients with HER2-positive early breast cancer Studies are ongoing to address optimal treatment duration Development of new anti-her2 treatment regimens will lead to greater patient benefits
Adjuvant Chemotherapy + Trastuzumab
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Chemotherapy + Trastuzumab (Optimal Drugs / Dosage / Trastuzumab) Adjuvant Chemotherapy (Optimal Drugs / Optimal Dosage
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationExiste-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon
Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon In 25 results of 4 Adjuvant Herceptin trials have definitively
More informationAppendix Four. Clinical effectiveness. Contents
Appendix Four. Clinical effectiveness Contents 1. Treatment regimens and available trial data... 1 Treatment regimes in randomised controlled trials... 1 Trial outcomes as reported... 10 2. Increasing
More informationHerceptin Pivotal Studies
Herceptin Pivotal Studies Nuhad K Ibrahim, MD, FACP Associate Professor of Medicine Breast Medical Oncology Department MD Anderson Cancer Center Houston, TX, USAE-mail: nibrahim@mdanderson.org Herceptin
More informationTreatment of Early Stage HER2-positive Breast Cancer (One size does not fit all)
Treatment of Early Stage HER2-positive Breast Cancer (One size does not fit all) 8 November 2014 Edward H. Romond, M.D. Professor of Medicine Lucille Parker Markey Cancer Center University of Kentucky
More informationTreatment of HER-2 positive breast cancer
EJC SUPPLEMENTS 6 (2008) 21 25 available at www.sciencedirect.com journal homepage: www.ejconline.com Treatment of HER-2 positive breast cancer Matteo Clavarezza, Marco Venturini * Ospedale Sacro Cuore
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationThe HERA Study Team. Presented by Ian E. Smith
Trastuzumab Following Adjuvant Chemotherapy in HER2-Positive Early Breast Cancer (HERA Trial): Disease-Free and Overall Survival after 2 Year Median Follow-Up The HERA Study Team Presented by Ian E. Smith
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationStopping a cancer trial early: is it really for the benefit of patients? What about the quality of data?
Stopping a cancer trial early: is it really for the benefit of patients? What about the quality of data? Pinuccia Valagussa Fondazione Michelangelo, Milano I have no relevant relationships to disclose
More informationTreatment of Early Stage HER2-positive Breast Cancer
Treatment of Early Stage HER2-positive Breast Cancer 3 November 2012 Edward H. Romond, M.D. Professor of Medicine Lucille Parker Markey Cancer Center University of Kentucky Lexington, KY Molecular Portrait
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationBIOLOGICAL THERAPIES FOR BREAST CANCER Updates from the 2005 San Antonio Breast Cancer Symposium
Emerging trends and recommendations BIOLOGICAL THERAPIES FOR BREAST CANCER Updates from the 2005 San Antonio Breast Cancer Symposium Joseph Ragaz, MD, FRCPC Top-line summary Here, Oncology Exchange presents
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More information(Neo) Adjuvant systemic therapy for HER-2+ EBC
(Neo) Adjuvant systemic therapy for HER-2+ EBC F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESMO Board of Directors & NR Committee Chair ESO Breast Cancer Program
More informationDo we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD
Do we have to change our anti-cancer strategy in case of cardiac toxicity? Point of view of the oncologist Guy Jerusalem, MD, PhD CHU Sart Tilman Liège Anticancer therapy: cardiac toxicity New anticancer
More informationAdjuvant Targeted Therapy in Early Breast Cancer
Adjuvant Targeted Therapy in Early Breast Cancer John Mackey, MD 1, Deanna McLeod, BSc 2, Joseph Ragaz, MD 3, Karen Gelmon, MD 4, Sunil Verma, MD 5, Kathleen Pritchard, MD 5, Kara Laing, MD 6, Louise Provencher,
More informationTreatment of Early-Stage HER2+ Breast Cancer
Treatment of Early-Stage HER2+ Breast Cancer Chau T. Dang, MD Chief, MSK Westchester Medical Oncology Service Breast Medicine Service Memorial Sloan Kettering Cancer Center Disclosures I have research
More informationQuality & Quantity of life in oncology What the CT doesn t tell us. Baby boomers have gone grey!
Quality & Quantity of life in oncology What the CT doesn t tell us Peter Harper Guys Hospital, London UK Baby boomers have gone grey! 57 % of patients with cancer are over 65 Number of people over 65 yrs
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationTRANSPARENCY COMMITTEE OPINION. 15 February 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More information(NEO-)ADJUVANT THERAPY FOR HER-2+ EBC
(NEO-)ADJUVANT THERAPY FOR HER-2+ EBC Rebecca Dent, MD FRCP (Canada) Senior Consultant, National Cancer Center Singapore Associate Professor, Duke-NUS www.abc-lisbon.org When to question a pathology report?
More informationSANDRA M. SWAIN. Washington Cancer Institute, Washington, District of Columbia, USA
The Oncologist Early-Stage Breast Cancer: Clinical Update Chemotherapy: Updates and New Perspectives SANDRA M. SWAIN Washington Cancer Institute, Washington, District of Columbia, USA Key Words. Breast
More informationSANDRA M. SWAIN. Washington Cancer Institute, Washington, District of Columbia, USA
The Oncologist Chemotherapy: Updates and New Perspectives SANDRA M. SWAIN Washington Cancer Institute, Washington, District of Columbia, USA Key Words. Breast cancer Chemotherapy Taxane Trastuzumab Ki-67
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More informationLondon, 22 May 2006 Product Name: Herceptin Procedure no.: EMEA/H/C/278/II/0026 SCIENTIFIC DISCUSSION
London, 22 May 2006 Product Name: Herceptin Procedure no.: EMEA/H/C/278/II/0026 SCIENTIFIC DISCUSSION 1 Introduction Trastuzumab is currently approved for the treatment of Her2 over-expressing metastatic
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer
Key Findings to Date in the Neoadjuvant Therapy of H2+ Breast Cancer Novel Preoperative Therapies for H2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive
More informationHerceptin (Trastuzumab): Adjuvant and Neoadjuvant Trials
Herceptin (Trastuzumab): Adjuvant and Neoadjuvant Trials Neora Yaal-Hahoshen MD and Tamar Safra MD Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Affiliated to Sackler Faculty
More informationMEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong
More informationAppendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
More informationNeoadjuvant and Adjuvant Therapy for HER2 Positive Disease
ADJUVANT AND NEOADJUVANT THERAPY FOR HER2-POSITIVE DISEASE Neoadjuvant and Adjuvant Therapy for HER2 Positive Disease Stephen K. Chia, MD, FRCP(C) OVERVIEW Since the initial description of the HER2 proto-oncogene
More information2
1 2 Systematic review of published evidence PUBMED 1999-2017 ASCO 1999-2017 SABCS 1999-2017 ECCO/ESMO 1999-2017 3 Statement: Anthracycline/ taxane based chemotherapy 1. Budd GT et al. SWOG S0221: A Phase
More informationFDA Briefing Document Oncologic Drugs Advisory Committee Meeting. September 12, sbla /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc.
/51 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting September 12, 2013 /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc. Disclaimer: The attached package contains background information
More informationAdjuvant Chemotherapy TNBC & HER2 Subtype
Adjuvant Chemotherapy TNBC & HER2 Subtype 2015.08.15 Gun Min Kim Yonsei Cancer Center Division of Medical Oncology Department of Internal Medicine Yonsei University College of Medicine gmkim77@yuhs.ac
More informationTrastuzumab in the adjuvant setting: a practical review
Therapy in Practice Trastuzumab in the adjuvant setting: a practical review Trastuzumab is a monoclonal antibody directed against the product of the HER2/neu oncogene. The HER2 protein is overexpressed
More informationASCO 2017 BREAST CANCER HIGHLIGHTS
Post-ASCO 24 th June 2017, Dolce La Hulpe, Belgium ASCO 2017 BREAST CANCER HIGHLIGHTS Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationCASE STUDIES CLINICAL CASE SCENARIOS. Matthew J. Ellis, MD, PhD
CLINICAL CASE SCENARIOS Matthew J. Ellis, MD, PhD Clinicians face daily challenges in the management of individual patients with breast cancer who demonstrate different characteristics in terms of estrogen
More information新竹馬偕紀念醫院癌症中心 乳癌化學治療藥物處方
新竹馬偕紀念醫院癌症中心 乳癌化學治療藥物處方 文件修訂記錄 修正次數 修正日期 修正版別 修 改 內 容 1 2011.04.07 1.0 初次訂定 2 2013.05.08 2.0 修訂 3 2013.04.30 3.0 修訂 :Triple-Negative Breast Cancer 處方 新增 :Neoadjuvant-p7~8 4 2014.04.29 4.0 修訂 :FEC + Trastuzumab
More informationTaxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1
Important data from BCIRG 006 Taxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1 in the adjuvant treatment of HER2+ breast
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationNeoadjuvantTreatment In BC When, How, Who?
NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of
More informationTrastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer neoadjuvant treatment
Trastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer neoadjuvant treatment August 2010 This technology summary is based on information available at the time
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationthat the best available evidence has not demonstrated that pcr can predict long-term outcomes in the neoadjuvant setting.
pcr in one arm of a randomized clinical trial comparing two neoadjuvant chemotherapies predicts for improved event-free or overall survival in that arm of the clinical trial. perc noted that the NeoALTTO
More informationCurrent and Future perspectives of HER2+ BC
2018.4.6 GBCC Satellite symposium Current and Future perspectives of HER2+ BC Jee Hyun Kim, M.D., Ph.D. Seoul National University Bundang Hospital Seoul National University College of Medicine Disclaimer
More information(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer)
(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Neoadjuvant
More informationMatters of the heart: cardiac toxicity of adjuvant systemic therapy for earlystage breast cancer
CARDIAC TOXICITY MEDICAL ONCOLOGY Matters of the heart: cardiac toxicity of adjuvant systemic therapy for earlystage breast cancer K. Towns MD,* P.L. Bedard MD, and S. Verma MD MSEd ABSTRACT Breast cancer
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationShould pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results?
Commentary Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results? Tom Wei-Wu Chen 1, Ching-Hung Lin 1,2, Chiun-Sheng Huang 3 1 Department of Oncology,
More informationClinical Expert Submission Template
Clinical Expert Submission Template Thank you for agreeing to give us a personal statement on your view of the technology and the way it should be used in the NHS. Health care professionals can provide
More informationHERCEPTIN is a sterile, white to pale yellow, preservative-free lyophilized powder for intravenous (IV) infusion.
NAME OF THE MEDICINE HERCEPTIN trastuzumab CAS-180288-69-1 HERCEPTIN (trastuzumab) is a recombinant DNA-derived humanized monoclonal antibody that selectively targets the extracellular domain of the human
More informationBreast Cancer: Chemotherapy and Novel Agents
North Carolina Oncology Association & South Carolina Oncology Society Joint Membership Meeting ~ February 26 27, 2010 The Ballantyne Resort ~ Charlotte, NC Breast Cancer: Chemotherapy and Novel Agents
More informationChemotherapy for Isolated Locoregional Recurrence
Chemotherapy for Isolated Locoregional Recurrence Michelle Melisko MD Assistant Clinical Professor UCSF Helen Diller Family Comprehensive Cancer Center MBC and Improved Median Survival with New Therapies
More informationHow to carry out health technology appraisals and guidance. Learning from the Scottish experience Richard Clark, Principal Pharmaceutical
The Managed Introduction of New Medicines How to carry out health technology appraisals and guidance. Learning from the Scottish experience Richard Clark, Principal Pharmaceutical Analyst July 10 th 2009,
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationChapter. Contents Breast Cancer Adjuvant Epirubicin weekly. Docetaxel Copy No:
Chapter 2: Breast Cancer Contents Chapter 2: Breast Cancer... 1 Breast Cancer... 2 Adjuvant...... 2 Epi-CMF... 2 FEC / docetaxel... 3 FEC100... 4 AC/EC/TC... 4 (neo) adjuvant... 5... 5 HER2 positive: TCarboH...
More informationDESCRIPTION Herceptin is a sterile, white to pale yellow, preservative-free lyophilized powder for IV infusion.
NAME OF THE MEDICINE Herceptin trastuzumab (rch) Powder for Intravenous (IV) Infusion CAS-180288-69-1 Herceptin (trastuzumab) is a recombinant DNA-derived humanized monoclonal antibody that selectively
More informationThe Expert Thoughts. Alessandra Fabi Oncologia Medica 1
The Expert Thoughts Alessandra Fabi Oncologia Medica 1 My Thoughts Neoadjuvant: from the lessons of the history Adjuvant: Escalation and De-escalation Advanced and HER2+ : field for immunomodulation Brain
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Pertuzumab (Perjeta) Neoadjuvant Breast Cancer April 30, 2015
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Pertuzumab (Perjeta) Neoadjuvant Breast Cancer April 30, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationBREAST CANCER RISK REDUCTION (PREVENTION)
BREAST CANCER RISK REDUCTION (PREVENTION) Articles Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled
More information30 TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) NEW ADVANCES IN THE TREATMENT OF BREAST CANCER
EDUCATIONAL HIGHLIGHTS FROM DATA PRESENTED AT THE 30 TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) NEW ADVANCES IN THE TREATMENT OF BREAST CANCER DECEMBER 13 16, 2007, SAN ANTONIO, TX, USA 2 CONTENTS
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationDR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA
Recent Advances of Docetaxel in Management of Breast Cancer DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA 1 ADJUVANT
More informationFEC-T plus trastuzumab & pertuzumab
Page 1 of 5 Indication Treatment Intent Frequency and number of cycles Monitoring parameters pre-treatment The neoadjuvant treatment of locally advanced, inflammatory or early HER2 positive breast cancer
More informationTITLE PAGE STUDY REPORT NO
TITLE PAGE STUDY REPORT NO. 1075544 From Final Study Report: RO0452317 - F. Hoffmann-L a Roche Ltd Protocol BO20652 Report Number 1075544 1 PASS INFORMATION TITLE: AN OBSERVATIONAL STUDY OF CARDIAC EVENTS
More informationHer 2 Positive Metastatic Breast Cancer
Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationevidence watch landmarks A review and assessment of recent clinical trial data Follicular non-hodgkin lymphoma Latest research profiles
Latest research profiles evidence watch A review and assessment of recent clinical trial data Oncology Exchange provides overviews of important clinical trial data presented at the 49 th Annual Meeting
More informationNon-anthracycline Adjuvant regimens in N(-) Early Breast Cancer. Yeesoo Chae, MD, PhD Medical Oncology Kyungpook National University Medical Center
Non-anthracycline Adjuvant regimens in N(-) Early Breast Cancer Yeesoo Chae, MD, PhD Medical Oncology Kyungpook National University Medical Center Case: Clinical history F/45, Premenopause C/C: Rt. Palpable
More informationShould trastuzumab be administered concomitantly with anthracycline in women with early, HER2-positive breast cancer?
Breast Cancer Should trastuzumab be administered concomitantly with anthracycline in women with early, HER2-positive breast cancer? Filippo Montemurro Unit of Investigative Clinical Oncology, Division
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More information亞東紀念醫院 Breast Cancer 化學治療處方集
亞東紀念醫院 Breast Cancer 化學治療處方集 2008-08 制定 最近修改日期 :2015-01 CMF Breast cancer 化學治療處方參考集 Adjuvant Classic CMF Cyclophosphamide 100mg/m2 PO qd; D1-D14 Methotrexate 40mg/m 2 in N/S 100 ml IV drip 30 mins; D1,
More informationoriginal articles introduction
Annals of Oncology 19. List HJ, Reiter R, Singh B et al. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat 2001; 68: 21 28. 20. Jansson A, Delander
More informationNon-anthracycline Adjuvant regimens in Early Breast Cancer. Yeesoo Chae, MD, PhD Medical Oncology Kyungpook National University Medical Center
Non-anthracycline Adjuvant regimens in Early Breast Cancer Yeesoo Chae, MD, PhD Medical Oncology Kyungpook National University Medical Center Contents Role of Anthracyclines in adjuvant treatment EBCTCG2012
More informationKey Words. Trastuzumab Adjuvant chemotherapy Breast cancer HER-2 Systematic review Meta-analysis
The Oncologist Breast Cancer Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials ISSA J. DAHABREH, a,b HELEN LINARDOU,
More informationNuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento
Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento Prof. Sabino De Placido Dip. di Endocrinologia ed Oncologia
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationAny News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016
Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016 Yes! Age disparities vary by tumor subtype Genomic risk prediction data in young women Adjuvant systemic therapy
More information